Clinical trial · ClinicalTrials.gov
A Study of Retatrutide in Participants With Obesity or Overweight
NCT05567796
Trial identity
- Registry
- ClinicalTrials.gov
- Registry ID
- NCT05567796
- Phase
- Phase 3
- Design
- Interventional
- Allocation
- Randomized
- Masking
- Double-blind
- Overall status
- Recruiting
- Result status
- none
Sponsors & collaborators
- Sponsor
- Eli Lilly
- Collaborators
- —
Intervention assets
Arms
| Arm | Intervention | Enrollment |
|---|---|---|
| Retatrutide 1 mg | retatrutide 1 mg once weekly | — |
| Retatrutide 4 mg | retatrutide 4 mg once weekly | — |
| Retatrutide 12 mg | retatrutide 12 mg once weekly | — |
| Placebo | placebo once weekly | — |
Population & enrollment
- Population summary
- Adults with obesity or overweight with weight-related comorbidities.
- Eligibility summary
- BMI ≥30 or ≥27 with comorbidity.
- Planned enrollment
- 3000
- Actual enrollment
- 3000
Endpoints
- Primary endpoint
Percent change in body weight from baseline
- Secondary endpoints
Weight loss thresholds
Cardiometabolic endpoints
Dates
- Start date
- Sep 8, 2022
- Primary completion
- Jun 1, 2026
- Completion date
- Dec 1, 2026
- Last synced
- Aug 15, 2024
Locations
- Multiple countries
Plain-language interpretation
A Study of Retatrutide in Participants With Obesity or Overweight is a Phase 3 Interventional sponsored by Eli Lilly. It is evaluating Retatrutide in Adults with obesity or overweight with weight-related comorbidities.. The primary endpoint is Percent change in body weight from baseline.
Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against ClinicalTrials.gov.
Sources
- registryprimary record
A study of retatrutide (LY3437943) in participants with obesity
Eli Lilly and Company · ClinicalTrials.gov · Sep 8, 2022 · NCT05567796